US FDA extends review of KalVista's swelling disorder drug due to heavy workload

ReutersJun 13, 2025 8:12 PM

June 13 (Reuters) - The U.S. Food and Drug Administration extended the review of KalVista Pharmaceuticals' KALV.O drug for a type of hereditary swelling disorder due to heavy workload and limited resources, the company said on Friday.

The FDA indicated that it expects to deliver a decision within approximately four weeks, KalVista said.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Positive US Tech Earnings Outlook and Easing US-Iran Tensions Drive Japan and South Korea Stocks to Record Highs Again

In early Asian trading on April 27, driven by positive earnings expectations for U.S. tech companies, demand for AI-related stocks such as chips and semiconductors surged, propelling Japanese and South Korean equity markets to record highs. The Nikkei 225 Index touched an intraday high of 60,348.83 points; as of press time, it was up 0.7% at 60,135.21 points. South Korea's KOSPI Index reached a session high of 6,603.01 points and remained up 1.66% at 6,583.07 points as of press time.

TradingKey’s The Week on Wall Street: S&P 7,000 Breakthrough, Q1 Earnings Surge, and Fed Rate Projections

S&P 500 breaks 7,000 amid Middle East de-escalation and strong Q1 earnings. Features inflation data insights, Fed rate projections, and a preview of upcoming FOMC meetings and retail sales reports for strategic investor positioning.

Tesla Stock Forecast: How Much Will TSLA Stock Be Worth in 2030? Can It Hit $3,000?

Explore the Tesla stock forecast for 2030. This analysis covers TSLA’s pivot to AI, Robotaxis, and Optimus robotics, evaluating bull and bear cases for the $3,000 price target. Gain insights into market cap projections and key growth drivers for long-term investors.

Fed FOMC Preview: No Rate Cuts Become Consensus, Warsh Succession Imminent

TradingKey - The Federal Reserve is scheduled to hold its monetary policy meeting on April 28-29, with the market widely expecting interest rates to be maintained between 3.50% and 3.75% for the third consecutive time. CME FedWatch data indicates that the market has fully priced in expectations for the Fed to hold steady this month.

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

TradingKey - U.S. e-commerce giant Amazon (AMZN) is scheduled to release its first-quarter 2026 financial results on April 29. According to the latest market consensus estimates from financial data platform FactSet, the company’s Q1 revenue is expected to reach $177.2 billion, up 13% year-over-year, while adjusted earnings per share (EPS) are projected at $1.63.

Featured Tools